Milovanović, Zorka M.

Link to this page

Authority KeyName Variants
70e6eba8-a6cc-4468-9391-01167fcfc026
  • Milovanović, Zorka M. (11)
  • Milovanović, Zorka (1)
Projects

Author's Bibliography

Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer

Nedeljković, Milica; Tanić, Nasta; Prvanović, Mirjana; Milovanović, Zorka; Tanić, Nikola

(2021)

TY  - JOUR
AU  - Nedeljković, Milica
AU  - Tanić, Nasta
AU  - Prvanović, Mirjana
AU  - Milovanović, Zorka
AU  - Tanić, Nikola
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9173
AB  - Background: ATP-binding cassette (ABC) transporters are responsible for the efflux of a wide variety of anti-cancer agents and have been implicated in the chemoresistance of various solid tumors. Chemoresistance is a major cause of therapeutic failure, especially in the highly aggressive triple-negative breast cancer (TNBC) in which, unlike estrogen receptor-expressing (ER+) BC, both endocrine and targeted treatments are ineffectual. We aimed to investigate the level and frequency of expression of the three most important ABC transporter, ABCG2, ABCC1, and ABCB1, according to breast cancer subtype. Methods: We evaluated ABCG2, ABCC1, and ABCB1 protein expressions in 124 primary breast tumors (78 samples were classified as TNBC, while 46 were classified as ER+) by immunohistochemistry and correlated it to clinicopathological characteristics and outcome. Results: All three transporters had significantly higher expression and were more frequently expressed in TNBC compared to ER+ tumors (p < 0.0001). ABCG2 and ABCC1 had a very high level of expression in TNBC that was significantly greater compared to ABCB1 (p < 0.0001). ABCB1 expression was associated with TNBC metastatic spread (p = 0.03). In contrast, TNBC patients with high ABCG2 expression level had significantly longer disease-free interval (p = 0.03) and overall survival (p = 0.007). Conclusion: ABCG2, ABCC1, and ABCB1 expression in breast cancer is subtype-specific and associated with triple-negative tumors. The expression of ABCB1 may be useful as a marker of metastatic spread. Moreover, unexpectedly, our results showed a beneficial effect of ABCG2 expression on TNBC clinical behavior. These findings could have implications for the implementation of future TNBC treatment strategies.
T2  - Breast Cancer
T1  - Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer
VL  - 28
IS  - 3
SP  - 727
EP  - 736
DO  - 10.1007/s12282-020-01210-z
ER  - 
@article{
author = "Nedeljković, Milica and Tanić, Nasta and Prvanović, Mirjana and Milovanović, Zorka and Tanić, Nikola",
year = "2021",
abstract = "Background: ATP-binding cassette (ABC) transporters are responsible for the efflux of a wide variety of anti-cancer agents and have been implicated in the chemoresistance of various solid tumors. Chemoresistance is a major cause of therapeutic failure, especially in the highly aggressive triple-negative breast cancer (TNBC) in which, unlike estrogen receptor-expressing (ER+) BC, both endocrine and targeted treatments are ineffectual. We aimed to investigate the level and frequency of expression of the three most important ABC transporter, ABCG2, ABCC1, and ABCB1, according to breast cancer subtype. Methods: We evaluated ABCG2, ABCC1, and ABCB1 protein expressions in 124 primary breast tumors (78 samples were classified as TNBC, while 46 were classified as ER+) by immunohistochemistry and correlated it to clinicopathological characteristics and outcome. Results: All three transporters had significantly higher expression and were more frequently expressed in TNBC compared to ER+ tumors (p < 0.0001). ABCG2 and ABCC1 had a very high level of expression in TNBC that was significantly greater compared to ABCB1 (p < 0.0001). ABCB1 expression was associated with TNBC metastatic spread (p = 0.03). In contrast, TNBC patients with high ABCG2 expression level had significantly longer disease-free interval (p = 0.03) and overall survival (p = 0.007). Conclusion: ABCG2, ABCC1, and ABCB1 expression in breast cancer is subtype-specific and associated with triple-negative tumors. The expression of ABCB1 may be useful as a marker of metastatic spread. Moreover, unexpectedly, our results showed a beneficial effect of ABCG2 expression on TNBC clinical behavior. These findings could have implications for the implementation of future TNBC treatment strategies.",
journal = "Breast Cancer",
title = "Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer",
volume = "28",
number = "3",
pages = "727-736",
doi = "10.1007/s12282-020-01210-z"
}
Nedeljković, M., Tanić, N., Prvanović, M., Milovanović, Z.,& Tanić, N.. (2021). Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer. in Breast Cancer, 28(3), 727-736.
https://doi.org/10.1007/s12282-020-01210-z
Nedeljković M, Tanić N, Prvanović M, Milovanović Z, Tanić N. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer. in Breast Cancer. 2021;28(3):727-736.
doi:10.1007/s12282-020-01210-z .
Nedeljković, Milica, Tanić, Nasta, Prvanović, Mirjana, Milovanović, Zorka, Tanić, Nikola, "Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer" in Breast Cancer, 28, no. 3 (2021):727-736,
https://doi.org/10.1007/s12282-020-01210-z . .
3
3
2

Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer

Nedeljković, Milica; Tanić, Nikola; Dramićanin, Tatjana; Milovanović, Zorka M.; Šušnjar, Snežana; Milinković, Vedrana; Vujović, Ivana; Tanić, Nasta

(2018)

TY  - JOUR
AU  - Nedeljković, Milica
AU  - Tanić, Nikola
AU  - Dramićanin, Tatjana
AU  - Milovanović, Zorka M.
AU  - Šušnjar, Snežana
AU  - Milinković, Vedrana
AU  - Vujović, Ivana
AU  - Tanić, Nasta
PY  - 2018
UR  - http://content.sciendo.com/view/journals/jomb/ahead-of-print/article-10.1515-jomb-2018-0012.xml
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/7683
AB  - © 2018 Milica Nedeljković et al., published by De Gruyter Open 2018. Background: Triple negative breast cancer (TNBC) is characterized by aggressive clinical course and is unresponsive to anti-HER2 and endocrine therapy. TNBC is difficult to treat and is often lethal. Given the need to find new targets for therapy we explored clinicopathological significance of copy number gain of FGFR1 and c-MYC. Our aim was to determine the impact of FGFR1 and c-MYC copy number gain on clinical course and outcome of TNBC. Methods: FGFR1 and c-MYC gene copy number alterations were evaluated in 78 archive TNBC samples using TaqMan based quantitative real time PCR assays. Results: 50% of samples had increased c-MYC copy number. c-MYC copy number gain was associated with TNBC in contrast to ER positive cancers. Our results showed significant correlation between c-MYC copy number gain and high grade of TNBCs. This suggests that c-MYC copy number could be an useful prognostic marker for TNBC patients. c-MYC copy number gain was associated with high pTNM stage as well as lobular and medullary tumor subtypes. 43% of samples had increased FGFR1 copy number. No correlations between FGFR1 copy number gain and clinicopathological variables were observed. Conclusions: We identified c-MYC copy number gain as a prognostic marker for TNBC. Our results indicate that c- MYC may contribute to TNBC progression. We observed no significant association between c-MYC and/or FGFR1 copy number status and patient survival.
T2  - Journal of Medical Biochemistry
T1  - Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer
T1  - Značaj promena broja kopija FGFR1 i c-MYC gena u trostruko negativnim karcinomima dojke
VL  - 37
IS  - 2
SP  - 1
EP  - 8
DO  - 10.1515/jomb-2018-0012
ER  - 
@article{
author = "Nedeljković, Milica and Tanić, Nikola and Dramićanin, Tatjana and Milovanović, Zorka M. and Šušnjar, Snežana and Milinković, Vedrana and Vujović, Ivana and Tanić, Nasta",
year = "2018",
abstract = "© 2018 Milica Nedeljković et al., published by De Gruyter Open 2018. Background: Triple negative breast cancer (TNBC) is characterized by aggressive clinical course and is unresponsive to anti-HER2 and endocrine therapy. TNBC is difficult to treat and is often lethal. Given the need to find new targets for therapy we explored clinicopathological significance of copy number gain of FGFR1 and c-MYC. Our aim was to determine the impact of FGFR1 and c-MYC copy number gain on clinical course and outcome of TNBC. Methods: FGFR1 and c-MYC gene copy number alterations were evaluated in 78 archive TNBC samples using TaqMan based quantitative real time PCR assays. Results: 50% of samples had increased c-MYC copy number. c-MYC copy number gain was associated with TNBC in contrast to ER positive cancers. Our results showed significant correlation between c-MYC copy number gain and high grade of TNBCs. This suggests that c-MYC copy number could be an useful prognostic marker for TNBC patients. c-MYC copy number gain was associated with high pTNM stage as well as lobular and medullary tumor subtypes. 43% of samples had increased FGFR1 copy number. No correlations between FGFR1 copy number gain and clinicopathological variables were observed. Conclusions: We identified c-MYC copy number gain as a prognostic marker for TNBC. Our results indicate that c- MYC may contribute to TNBC progression. We observed no significant association between c-MYC and/or FGFR1 copy number status and patient survival.",
journal = "Journal of Medical Biochemistry",
title = "Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer, Značaj promena broja kopija FGFR1 i c-MYC gena u trostruko negativnim karcinomima dojke",
volume = "37",
number = "2",
pages = "1-8",
doi = "10.1515/jomb-2018-0012"
}
Nedeljković, M., Tanić, N., Dramićanin, T., Milovanović, Z. M., Šušnjar, S., Milinković, V., Vujović, I.,& Tanić, N.. (2018). Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer. in Journal of Medical Biochemistry, 37(2), 1-8.
https://doi.org/10.1515/jomb-2018-0012
Nedeljković M, Tanić N, Dramićanin T, Milovanović ZM, Šušnjar S, Milinković V, Vujović I, Tanić N. Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer. in Journal of Medical Biochemistry. 2018;37(2):1-8.
doi:10.1515/jomb-2018-0012 .
Nedeljković, Milica, Tanić, Nikola, Dramićanin, Tatjana, Milovanović, Zorka M., Šušnjar, Snežana, Milinković, Vedrana, Vujović, Ivana, Tanić, Nasta, "Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer" in Journal of Medical Biochemistry, 37, no. 2 (2018):1-8,
https://doi.org/10.1515/jomb-2018-0012 . .
1

Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue

Ivanović, Vesna; Dedović-Tanić, Nasta; Milovanović, Zorka M.; Lukić, Silvana; Nikolic, Srdjan; Baltic, Vladimir; Stojiljković, Bratislav; Demajo, Miroslav; Mandušić, Vesna; Dimitrijević, Bogomir B.

(2016)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Dedović-Tanić, Nasta
AU  - Milovanović, Zorka M.
AU  - Lukić, Silvana
AU  - Nikolic, Srdjan
AU  - Baltic, Vladimir
AU  - Stojiljković, Bratislav
AU  - Demajo, Miroslav
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/1327
AB  - We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.
T2  - Personalized Medicine
T1  - Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue
VL  - 13
IS  - 6
SP  - 523
EP  - 530
DO  - 10.2217/pme-2016-0032
ER  - 
@article{
author = "Ivanović, Vesna and Dedović-Tanić, Nasta and Milovanović, Zorka M. and Lukić, Silvana and Nikolic, Srdjan and Baltic, Vladimir and Stojiljković, Bratislav and Demajo, Miroslav and Mandušić, Vesna and Dimitrijević, Bogomir B.",
year = "2016",
abstract = "We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.",
journal = "Personalized Medicine",
title = "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue",
volume = "13",
number = "6",
pages = "523-530",
doi = "10.2217/pme-2016-0032"
}
Ivanović, V., Dedović-Tanić, N., Milovanović, Z. M., Lukić, S., Nikolic, S., Baltic, V., Stojiljković, B., Demajo, M., Mandušić, V.,& Dimitrijević, B. B.. (2016). Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue. in Personalized Medicine, 13(6), 523-530.
https://doi.org/10.2217/pme-2016-0032
Ivanović V, Dedović-Tanić N, Milovanović ZM, Lukić S, Nikolic S, Baltic V, Stojiljković B, Demajo M, Mandušić V, Dimitrijević BB. Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue. in Personalized Medicine. 2016;13(6):523-530.
doi:10.2217/pme-2016-0032 .
Ivanović, Vesna, Dedović-Tanić, Nasta, Milovanović, Zorka M., Lukić, Silvana, Nikolic, Srdjan, Baltic, Vladimir, Stojiljković, Bratislav, Demajo, Miroslav, Mandušić, Vesna, Dimitrijević, Bogomir B., "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue" in Personalized Medicine, 13, no. 6 (2016):523-530,
https://doi.org/10.2217/pme-2016-0032 . .
1
1
1
1

Mutant P53 Protein Expression and Antioxidant Status Deficiency in Breast Cancer

Milićević, Zorka T.; Kasapović, Jelena; Gavrilović, Ljubica; Milovanović, Zorka M.; Bajić, Vladan P.; Spremo-Potparević, Biljana

(2014)

TY  - JOUR
AU  - Milićević, Zorka T.
AU  - Kasapović, Jelena
AU  - Gavrilović, Ljubica
AU  - Milovanović, Zorka M.
AU  - Bajić, Vladan P.
AU  - Spremo-Potparević, Biljana
PY  - 2014
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/113
AB  - It is well recognized that cancers develop and grow as a result of disordered function of tumor suppressor genes and oncogenes, which may be exploited for screening purposes. Extensive evidence indicated tumor suppressor protein p53 as candidate marker for mutation identification. We have investigated mutant p53 protein expression in human breast tumors in relation to antioxidant status deficiency. The study included 100 breast cancer patients. p53 protein expression was evaluated by Western blot assay and immunostaining using a CM-1, DO-7 and Pab240 antibodies. Antioxidant parameters and lipid peroxidation were estimated by biochemical analyses. Western blotting with epitope-specific monoclonal antibody Pab240 strongly suggests that nuclear extracts from breast cancer cells express mutant forms of p53. It is of interest that the mutant forms of p53 overexpression in conjunction with the appearance of nuclear bodies are observed in highly aggressive carcinomas. Expression of isoform Delta p53 (45 kDa) and isoform of similar to 29 kDa were more common in cases with LN metastasis. These studies point out the molecular consequences of oxidative stress (lipid peroxides, LP, p LT 0.001) and antioxidant status deficiency (copper, zinc superoxid dismutase, SOD, p LT 0.001; catalase, CAT, p LT 0.01; glutathione reductase, GR, p LT 0.001; glutathione, GSH, p LT 0.05) and indicate the importance of p53 mutation as the commonest genetic alteration detected in breast cancer cells. The expression of mutant p53 is correlated to increased lipid peroxides (0.346, p LT 0.05) and lowered antioxidant activity of CAT (- 0.437, p LT 0.01) in the breast cancer patients.
T2  - EXCLI Journal
T1  - Mutant P53 Protein Expression and Antioxidant Status Deficiency in Breast Cancer
VL  - 13
SP  - 691
EP  - 708
ER  - 
@article{
author = "Milićević, Zorka T. and Kasapović, Jelena and Gavrilović, Ljubica and Milovanović, Zorka M. and Bajić, Vladan P. and Spremo-Potparević, Biljana",
year = "2014",
abstract = "It is well recognized that cancers develop and grow as a result of disordered function of tumor suppressor genes and oncogenes, which may be exploited for screening purposes. Extensive evidence indicated tumor suppressor protein p53 as candidate marker for mutation identification. We have investigated mutant p53 protein expression in human breast tumors in relation to antioxidant status deficiency. The study included 100 breast cancer patients. p53 protein expression was evaluated by Western blot assay and immunostaining using a CM-1, DO-7 and Pab240 antibodies. Antioxidant parameters and lipid peroxidation were estimated by biochemical analyses. Western blotting with epitope-specific monoclonal antibody Pab240 strongly suggests that nuclear extracts from breast cancer cells express mutant forms of p53. It is of interest that the mutant forms of p53 overexpression in conjunction with the appearance of nuclear bodies are observed in highly aggressive carcinomas. Expression of isoform Delta p53 (45 kDa) and isoform of similar to 29 kDa were more common in cases with LN metastasis. These studies point out the molecular consequences of oxidative stress (lipid peroxides, LP, p LT 0.001) and antioxidant status deficiency (copper, zinc superoxid dismutase, SOD, p LT 0.001; catalase, CAT, p LT 0.01; glutathione reductase, GR, p LT 0.001; glutathione, GSH, p LT 0.05) and indicate the importance of p53 mutation as the commonest genetic alteration detected in breast cancer cells. The expression of mutant p53 is correlated to increased lipid peroxides (0.346, p LT 0.05) and lowered antioxidant activity of CAT (- 0.437, p LT 0.01) in the breast cancer patients.",
journal = "EXCLI Journal",
title = "Mutant P53 Protein Expression and Antioxidant Status Deficiency in Breast Cancer",
volume = "13",
pages = "691-708"
}
Milićević, Z. T., Kasapović, J., Gavrilović, L., Milovanović, Z. M., Bajić, V. P.,& Spremo-Potparević, B.. (2014). Mutant P53 Protein Expression and Antioxidant Status Deficiency in Breast Cancer. in EXCLI Journal, 13, 691-708.
Milićević ZT, Kasapović J, Gavrilović L, Milovanović ZM, Bajić VP, Spremo-Potparević B. Mutant P53 Protein Expression and Antioxidant Status Deficiency in Breast Cancer. in EXCLI Journal. 2014;13:691-708..
Milićević, Zorka T., Kasapović, Jelena, Gavrilović, Ljubica, Milovanović, Zorka M., Bajić, Vladan P., Spremo-Potparević, Biljana, "Mutant P53 Protein Expression and Antioxidant Status Deficiency in Breast Cancer" in EXCLI Journal, 13 (2014):691-708.
5

Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients

Tanić, Nasta; Milinković, Vedrana; Dramićanin, Tatjana; Nedeljković, Milica; Stankovic, Tijana; Milovanović, Zorka M.; Šušnjar, Snežana; Milosevic, Verica; Sosic-Jurjevic, Branka; Dzodic, Radan; Tanić, Nikola

(2013)

TY  - JOUR
AU  - Tanić, Nasta
AU  - Milinković, Vedrana
AU  - Dramićanin, Tatjana
AU  - Nedeljković, Milica
AU  - Stankovic, Tijana
AU  - Milovanović, Zorka M.
AU  - Šušnjar, Snežana
AU  - Milosevic, Verica
AU  - Sosic-Jurjevic, Branka
AU  - Dzodic, Radan
AU  - Tanić, Nikola
PY  - 2013
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5745
AB  - Background: Breast cancer is the most common form of cancer in women. It arises from multiple genetic changes in oncogenes and tumor suppressor genes. Among so far studied oncogenes relatively few, including epdermal growth factor receptor (EGFR), cyclinD1 (CCND1) and c-myc, have been found to play an important role in progression of this type of human malignancy. The aim of this study was to examine the prognostic potential of CCND1, c-myc and EGFR amplification and their possible cooperation in breast carcinogenesis. Methods: Copy number analyses of CCND1 and c-myc genes were done by TaqMan based quantitative real time PCR. Amplification status of EGFR was determined by differential PCR. Results: Amplification of CCND1, c-myc and EGFR oncogene has been found in 20.4%, 26.5% and 26.5% of breast cancer cases, respectively. Analysis showed that amplification of CCND1 oncogene was significantly associated with the stage II of disease while amplification of EGFR gene was significantly associated with overexpression of HER-2/neu. Tumour stage and expression of HER-2/neu appeared to be significant predictors of patients outcome. Stage I patients lived significantly longer then stage III patients (p=0.04) while patients with HER-2/neu overexpression had worse prognoses and lived significantly shorter (p=0.001). Finally, survival of patients who underwent hormone therapy only was significantly longer (p=0.001) then survival of the rest of patients. Conclusions: Amplification of CCND1 or EGFR oncogene is associated with the progression of breast cancer and bad prognosis. No co-ordination in amplification of CCND1, c-myc and EGFR oncogenes were established in this cohort of breast cancer patients.
T2  - Journal of Medical Biochemistry
T1  - Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients
VL  - 32
IS  - 4
DO  - 10.2478/jomb-2014-0005
ER  - 
@article{
author = "Tanić, Nasta and Milinković, Vedrana and Dramićanin, Tatjana and Nedeljković, Milica and Stankovic, Tijana and Milovanović, Zorka M. and Šušnjar, Snežana and Milosevic, Verica and Sosic-Jurjevic, Branka and Dzodic, Radan and Tanić, Nikola",
year = "2013",
abstract = "Background: Breast cancer is the most common form of cancer in women. It arises from multiple genetic changes in oncogenes and tumor suppressor genes. Among so far studied oncogenes relatively few, including epdermal growth factor receptor (EGFR), cyclinD1 (CCND1) and c-myc, have been found to play an important role in progression of this type of human malignancy. The aim of this study was to examine the prognostic potential of CCND1, c-myc and EGFR amplification and their possible cooperation in breast carcinogenesis. Methods: Copy number analyses of CCND1 and c-myc genes were done by TaqMan based quantitative real time PCR. Amplification status of EGFR was determined by differential PCR. Results: Amplification of CCND1, c-myc and EGFR oncogene has been found in 20.4%, 26.5% and 26.5% of breast cancer cases, respectively. Analysis showed that amplification of CCND1 oncogene was significantly associated with the stage II of disease while amplification of EGFR gene was significantly associated with overexpression of HER-2/neu. Tumour stage and expression of HER-2/neu appeared to be significant predictors of patients outcome. Stage I patients lived significantly longer then stage III patients (p=0.04) while patients with HER-2/neu overexpression had worse prognoses and lived significantly shorter (p=0.001). Finally, survival of patients who underwent hormone therapy only was significantly longer (p=0.001) then survival of the rest of patients. Conclusions: Amplification of CCND1 or EGFR oncogene is associated with the progression of breast cancer and bad prognosis. No co-ordination in amplification of CCND1, c-myc and EGFR oncogenes were established in this cohort of breast cancer patients.",
journal = "Journal of Medical Biochemistry",
title = "Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients",
volume = "32",
number = "4",
doi = "10.2478/jomb-2014-0005"
}
Tanić, N., Milinković, V., Dramićanin, T., Nedeljković, M., Stankovic, T., Milovanović, Z. M., Šušnjar, S., Milosevic, V., Sosic-Jurjevic, B., Dzodic, R.,& Tanić, N.. (2013). Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients. in Journal of Medical Biochemistry, 32(4).
https://doi.org/10.2478/jomb-2014-0005
Tanić N, Milinković V, Dramićanin T, Nedeljković M, Stankovic T, Milovanović ZM, Šušnjar S, Milosevic V, Sosic-Jurjevic B, Dzodic R, Tanić N. Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients. in Journal of Medical Biochemistry. 2013;32(4).
doi:10.2478/jomb-2014-0005 .
Tanić, Nasta, Milinković, Vedrana, Dramićanin, Tatjana, Nedeljković, Milica, Stankovic, Tijana, Milovanović, Zorka M., Šušnjar, Snežana, Milosevic, Verica, Sosic-Jurjevic, Branka, Dzodic, Radan, Tanić, Nikola, "Amplification of Cycline D1, C-Myc and Egfr Oncogenes in Tumour Samples of Breast Cancer Patients" in Journal of Medical Biochemistry, 32, no. 4 (2013),
https://doi.org/10.2478/jomb-2014-0005 . .
4
1
4

The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients

Tanić, Nikola; Milovanović, Zorka M.; Tanić, Nasta; Dzodic, Radan; Juranic, Zorica; Šušnjar, Snežana; Plesinac-Karapandzic, Vesna; Tatic, Svetislav; Dramićanin, Tatjana; Davidović, Radoslav S.; Dimitrijević, Bogomir B.

(2012)

TY  - JOUR
AU  - Tanić, Nikola
AU  - Milovanović, Zorka M.
AU  - Tanić, Nasta
AU  - Dzodic, Radan
AU  - Juranic, Zorica
AU  - Šušnjar, Snežana
AU  - Plesinac-Karapandzic, Vesna
AU  - Tatic, Svetislav
AU  - Dramićanin, Tatjana
AU  - Davidović, Radoslav S.
AU  - Dimitrijević, Bogomir B.
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/5073
AB  - Tamoxifen is a standard therapeutical treatment in patients with estrogen receptor positive breast carcinoma. However, less than 50% of estrogen receptor positive breast cancers do not respond to tamoxifen treatment whereas 40% of tumors that initially respond to treatment develop resistance over time. The underlying mechanisms for tamoxifen resistance are probably multifactorial but remain largely unknown. The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. The effect of PTEN inactivation on breast cancer progression and disease outcome was also analyzed. Reduced or completely lost PTEN expression was observed in 55.1% of samples, while 63.3% of samples displayed LOH of PTEN gene. Inactivation of PTEN immunoexpression significantly correlated with the PTEN loss of heterozygosity, suggesting LOH as the most important genetic mechanism for the reduction or complete loss of PTEN expression in primary breast carcinoma. Most importantly, LOH of PTEN and consequential reduction of its immunoexpression showed significant correlation with the recurrence of the disease. Besides, our study revealed that LOH of PTEN tumor suppressor was significantly associated with shorter disease free survival, breast cancer specific survival and overall survival. In summary, our results imply that LOH of PTEN could be used as a good prognostic characteristic for the outcome of breast cancer patients treated with tamoxifen.
T2  - Cancer Biology and Therapy
T1  - The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients
VL  - 13
IS  - 12
SP  - 1165
EP  - 1174
DO  - 10.4161/cbt.21346
ER  - 
@article{
author = "Tanić, Nikola and Milovanović, Zorka M. and Tanić, Nasta and Dzodic, Radan and Juranic, Zorica and Šušnjar, Snežana and Plesinac-Karapandzic, Vesna and Tatic, Svetislav and Dramićanin, Tatjana and Davidović, Radoslav S. and Dimitrijević, Bogomir B.",
year = "2012",
abstract = "Tamoxifen is a standard therapeutical treatment in patients with estrogen receptor positive breast carcinoma. However, less than 50% of estrogen receptor positive breast cancers do not respond to tamoxifen treatment whereas 40% of tumors that initially respond to treatment develop resistance over time. The underlying mechanisms for tamoxifen resistance are probably multifactorial but remain largely unknown. The primary aim of this study was to investigate the impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen by analyzing loss of heterozygosity (LOH) and immunohystochemical expression of PTEN in 49 primary breast carcinomas of patients treated with tamoxifen as the only adjuvant therapy. The effect of PTEN inactivation on breast cancer progression and disease outcome was also analyzed. Reduced or completely lost PTEN expression was observed in 55.1% of samples, while 63.3% of samples displayed LOH of PTEN gene. Inactivation of PTEN immunoexpression significantly correlated with the PTEN loss of heterozygosity, suggesting LOH as the most important genetic mechanism for the reduction or complete loss of PTEN expression in primary breast carcinoma. Most importantly, LOH of PTEN and consequential reduction of its immunoexpression showed significant correlation with the recurrence of the disease. Besides, our study revealed that LOH of PTEN tumor suppressor was significantly associated with shorter disease free survival, breast cancer specific survival and overall survival. In summary, our results imply that LOH of PTEN could be used as a good prognostic characteristic for the outcome of breast cancer patients treated with tamoxifen.",
journal = "Cancer Biology and Therapy",
title = "The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients",
volume = "13",
number = "12",
pages = "1165-1174",
doi = "10.4161/cbt.21346"
}
Tanić, N., Milovanović, Z. M., Tanić, N., Dzodic, R., Juranic, Z., Šušnjar, S., Plesinac-Karapandzic, V., Tatic, S., Dramićanin, T., Davidović, R. S.,& Dimitrijević, B. B.. (2012). The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. in Cancer Biology and Therapy, 13(12), 1165-1174.
https://doi.org/10.4161/cbt.21346
Tanić N, Milovanović ZM, Tanić N, Dzodic R, Juranic Z, Šušnjar S, Plesinac-Karapandzic V, Tatic S, Dramićanin T, Davidović RS, Dimitrijević BB. The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients. in Cancer Biology and Therapy. 2012;13(12):1165-1174.
doi:10.4161/cbt.21346 .
Tanić, Nikola, Milovanović, Zorka M., Tanić, Nasta, Dzodic, Radan, Juranic, Zorica, Šušnjar, Snežana, Plesinac-Karapandzic, Vesna, Tatic, Svetislav, Dramićanin, Tatjana, Davidović, Radoslav S., Dimitrijević, Bogomir B., "The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients" in Cancer Biology and Therapy, 13, no. 12 (2012):1165-1174,
https://doi.org/10.4161/cbt.21346 . .
27
24
32

Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report

Stanojević, Boban; Dzodic, Radan; Saenko, Vladimir; Milovanović, Zorka M.; Krstevski, Vesna; Radlovic, Petar; Buta, Marko; Rulic, Bozidar; Todorović, Lidija; Dimitrijević, Bogomir B.; Yamashita, Shunichi

(2012)

TY  - JOUR
AU  - Stanojević, Boban
AU  - Dzodic, Radan
AU  - Saenko, Vladimir
AU  - Milovanović, Zorka M.
AU  - Krstevski, Vesna
AU  - Radlovic, Petar
AU  - Buta, Marko
AU  - Rulic, Bozidar
AU  - Todorović, Lidija
AU  - Dimitrijević, Bogomir B.
AU  - Yamashita, Shunichi
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4970
AB  - Background: Struma ovarii (SO) is a rare form of ovarian mature teratoma in which thyroid tissue is the predominant element. Because of its rarity, the differential diagnosis between benign and malignant SO has not been clearly defined. It is believed that malignant transformation of SO has similar molecular features with and its prognosis corresponds to that of malignant tumors originating in the thyroid. Case presentation: We report 35-year-old woman with bilateral ovarian cysts incidentally detected by ultrasound during the first trimester of pregnancy. Four months after delivery of a healthy child without complication she was admitted to the hospital for acute abdominal pain. Laparoscopic left adnexectomy was performed initially in a regional hospital; right cystectomy was done later in a specialized clinic. Intraoperative frozen section and a final pathology revealed that the cyst from the left ovary was composed of mature teratomatous elements, normal thyroid tissue ( GT 50%) and a non-encapsulated focus of follicular variant of papillary thyroid carcinoma (PTC). Normal and cancerous thyroid tissues were tested for BRAF and RAS mutations by direct sequencing, and for RET/PTC rearrangements by RT-PCR/Southern blotting. A KRAS codon 12 mutation, the GGT - GT GTT transversion, corresponding to the Gly - GT Val amino acid change was identified in the absence of other genetic alterations commonly found in PTC. Conclusion: To the best of our knowledge, this is the first time this mutation is described in a papillary thyroid carcinoma arising in struma in the ovarii. This finding provides further evidence that even rare mutations specific for PTC may occur in such tumors. Molecular testing may be a useful adjunct to common differential diagnostic methods of thyroid malignancy in SO.
T2  - BMC Cancer
T1  - Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report
VL  - 12
DO  - 10.1186/1471-2407-12-224
ER  - 
@article{
author = "Stanojević, Boban and Dzodic, Radan and Saenko, Vladimir and Milovanović, Zorka M. and Krstevski, Vesna and Radlovic, Petar and Buta, Marko and Rulic, Bozidar and Todorović, Lidija and Dimitrijević, Bogomir B. and Yamashita, Shunichi",
year = "2012",
abstract = "Background: Struma ovarii (SO) is a rare form of ovarian mature teratoma in which thyroid tissue is the predominant element. Because of its rarity, the differential diagnosis between benign and malignant SO has not been clearly defined. It is believed that malignant transformation of SO has similar molecular features with and its prognosis corresponds to that of malignant tumors originating in the thyroid. Case presentation: We report 35-year-old woman with bilateral ovarian cysts incidentally detected by ultrasound during the first trimester of pregnancy. Four months after delivery of a healthy child without complication she was admitted to the hospital for acute abdominal pain. Laparoscopic left adnexectomy was performed initially in a regional hospital; right cystectomy was done later in a specialized clinic. Intraoperative frozen section and a final pathology revealed that the cyst from the left ovary was composed of mature teratomatous elements, normal thyroid tissue ( GT 50%) and a non-encapsulated focus of follicular variant of papillary thyroid carcinoma (PTC). Normal and cancerous thyroid tissues were tested for BRAF and RAS mutations by direct sequencing, and for RET/PTC rearrangements by RT-PCR/Southern blotting. A KRAS codon 12 mutation, the GGT - GT GTT transversion, corresponding to the Gly - GT Val amino acid change was identified in the absence of other genetic alterations commonly found in PTC. Conclusion: To the best of our knowledge, this is the first time this mutation is described in a papillary thyroid carcinoma arising in struma in the ovarii. This finding provides further evidence that even rare mutations specific for PTC may occur in such tumors. Molecular testing may be a useful adjunct to common differential diagnostic methods of thyroid malignancy in SO.",
journal = "BMC Cancer",
title = "Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report",
volume = "12",
doi = "10.1186/1471-2407-12-224"
}
Stanojević, B., Dzodic, R., Saenko, V., Milovanović, Z. M., Krstevski, V., Radlovic, P., Buta, M., Rulic, B., Todorović, L., Dimitrijević, B. B.,& Yamashita, S.. (2012). Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. in BMC Cancer, 12.
https://doi.org/10.1186/1471-2407-12-224
Stanojević B, Dzodic R, Saenko V, Milovanović ZM, Krstevski V, Radlovic P, Buta M, Rulic B, Todorović L, Dimitrijević BB, Yamashita S. Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. in BMC Cancer. 2012;12.
doi:10.1186/1471-2407-12-224 .
Stanojević, Boban, Dzodic, Radan, Saenko, Vladimir, Milovanović, Zorka M., Krstevski, Vesna, Radlovic, Petar, Buta, Marko, Rulic, Bozidar, Todorović, Lidija, Dimitrijević, Bogomir B., Yamashita, Shunichi, "Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report" in BMC Cancer, 12 (2012),
https://doi.org/10.1186/1471-2407-12-224 . .
1
16
16
16

Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia

Dzodic, Radan; Markovic, Ivan; Stanojević, Boban; Saenko, Vladimir; Buta, Marko; Đurišić, Igor; Oruci, Merima; Pupic, Gordana; Milovanović, Zorka M.; Yamashita, Shunichi

(2012)

TY  - JOUR
AU  - Dzodic, Radan
AU  - Markovic, Ivan
AU  - Stanojević, Boban
AU  - Saenko, Vladimir
AU  - Buta, Marko
AU  - Đurišić, Igor
AU  - Oruci, Merima
AU  - Pupic, Gordana
AU  - Milovanović, Zorka M.
AU  - Yamashita, Shunichi
PY  - 2012
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4922
AB  - Thyroglossal duct cyst (TDC) carcinoma is a comparable rare entity and treatment strategies have not been standardized. Here, we report a favorable outcome of TDC carcinoma patients based on our therapeutic strategy. Twelve patients with TDC carcinoma treated in our department from 1986 to 2012 were enrolled. Ten patients underwent Sistrunks procedure in other institutions and referred to our institution for re-operation after the diagnosis of TDC carcinoma and the remaining two underwent initial surgery in our institution. Eleven patients were diagnosed as papillary and one as follicular carcinoma originating from TDC. We performed total thyroidectomy for 11, and limited thyroidectomy for one patient. Three patients (25%) had carcinoma lesions in the thyroid. We routinely dissected level I bilaterally and 6 of 11 patients (55%) with papillary carcinoma-type TDC carcinoma had metastasis. Level II/III nodes were biopsied and if positive, we performed level II-IV dissection. Of the 5 patients positive for level II/III, 2 were also positive for level IV. For the 3 patients with synchronous carcinoma in the thyroid, we performed level VI dissection and two had metastasis in this level. To date, 1 patient showed a recurrence to the lung, but none of the patients in our series died of carcinoma. For surgery of TDC carcinoma, Sistrunks procedure, total thyroidectomy with level I dissection is mandatory. Whether level II-IV dissection is performed depends on pathology of biopsied level II/III nodes. Level VI dissection is also recommended especially when carcinoma lesions are pre/intra operatively detected in the thyroid.
T2  - Endocrine Journal
T1  - Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia
VL  - 59
IS  - 6
SP  - 517
EP  - 522
DO  - 10.1507/endocrj.EJ12-0070
ER  - 
@article{
author = "Dzodic, Radan and Markovic, Ivan and Stanojević, Boban and Saenko, Vladimir and Buta, Marko and Đurišić, Igor and Oruci, Merima and Pupic, Gordana and Milovanović, Zorka M. and Yamashita, Shunichi",
year = "2012",
abstract = "Thyroglossal duct cyst (TDC) carcinoma is a comparable rare entity and treatment strategies have not been standardized. Here, we report a favorable outcome of TDC carcinoma patients based on our therapeutic strategy. Twelve patients with TDC carcinoma treated in our department from 1986 to 2012 were enrolled. Ten patients underwent Sistrunks procedure in other institutions and referred to our institution for re-operation after the diagnosis of TDC carcinoma and the remaining two underwent initial surgery in our institution. Eleven patients were diagnosed as papillary and one as follicular carcinoma originating from TDC. We performed total thyroidectomy for 11, and limited thyroidectomy for one patient. Three patients (25%) had carcinoma lesions in the thyroid. We routinely dissected level I bilaterally and 6 of 11 patients (55%) with papillary carcinoma-type TDC carcinoma had metastasis. Level II/III nodes were biopsied and if positive, we performed level II-IV dissection. Of the 5 patients positive for level II/III, 2 were also positive for level IV. For the 3 patients with synchronous carcinoma in the thyroid, we performed level VI dissection and two had metastasis in this level. To date, 1 patient showed a recurrence to the lung, but none of the patients in our series died of carcinoma. For surgery of TDC carcinoma, Sistrunks procedure, total thyroidectomy with level I dissection is mandatory. Whether level II-IV dissection is performed depends on pathology of biopsied level II/III nodes. Level VI dissection is also recommended especially when carcinoma lesions are pre/intra operatively detected in the thyroid.",
journal = "Endocrine Journal",
title = "Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia",
volume = "59",
number = "6",
pages = "517-522",
doi = "10.1507/endocrj.EJ12-0070"
}
Dzodic, R., Markovic, I., Stanojević, B., Saenko, V., Buta, M., Đurišić, I., Oruci, M., Pupic, G., Milovanović, Z. M.,& Yamashita, S.. (2012). Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia. in Endocrine Journal, 59(6), 517-522.
https://doi.org/10.1507/endocrj.EJ12-0070
Dzodic R, Markovic I, Stanojević B, Saenko V, Buta M, Đurišić I, Oruci M, Pupic G, Milovanović ZM, Yamashita S. Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia. in Endocrine Journal. 2012;59(6):517-522.
doi:10.1507/endocrj.EJ12-0070 .
Dzodic, Radan, Markovic, Ivan, Stanojević, Boban, Saenko, Vladimir, Buta, Marko, Đurišić, Igor, Oruci, Merima, Pupic, Gordana, Milovanović, Zorka M., Yamashita, Shunichi, "Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia" in Endocrine Journal, 59, no. 6 (2012):517-522,
https://doi.org/10.1507/endocrj.EJ12-0070 . .
26
21
24

Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia

Stanojević, Boban; Dzodic, Radan; Saenko, Vladimir; Milovanović, Zorka M.; Pupic, Gordana; Zivkovic, Ognjen; Markovic, Ivan; Đurišić, Igor; Buta, Marko; Dimitrijević, Bogomir B.; Rogounovitch, Tatiana; Mitsutake, Norisato; Mine, Mariko; Shibata, Yoshisada; Nakashima, Masahiro; Yamashita, Shunichi

(2011)

TY  - JOUR
AU  - Stanojević, Boban
AU  - Dzodic, Radan
AU  - Saenko, Vladimir
AU  - Milovanović, Zorka M.
AU  - Pupic, Gordana
AU  - Zivkovic, Ognjen
AU  - Markovic, Ivan
AU  - Đurišić, Igor
AU  - Buta, Marko
AU  - Dimitrijević, Bogomir B.
AU  - Rogounovitch, Tatiana
AU  - Mitsutake, Norisato
AU  - Mine, Mariko
AU  - Shibata, Yoshisada
AU  - Nakashima, Masahiro
AU  - Yamashita, Shunichi
PY  - 2011
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4401
AB  - Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes. Our aim was to assess clinico-pathological and prognostic correlations of these PTC-specific gene alterations, with a particular emphasis on the BRAF mutation, in a group of 266 Serbian PTC patients, for the first time. The reference center-based retrospective cohort included 201 (75.6%) females and 65 (24.4%) males aged 48.0 +/- 16.1 years (8-83 years old, range) diagnosed and treated for PTC during 1993-2008. Follow-up period was 53.1 +/- 41.6 months (7-187 months, range). BRAF and RAS mutations were determined by direct sequencing of genomic DNA. RET/PTC rearrangements were analyzed by RT-PCR/Southern blotting. Genetic alterations were detected in 150/266 tumors (56.4%). One tumor displayed two genetic alterations. The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266(4.1%) and RET/PTC in 55/266(20.7%; 42/266 (15.8%)RET/PTC1 and 13/266 (4.9%)RET/PTC3). On multivariate analysis BRAF(V600E) was associated with the classical papillary morphology (P = 0.05), the higher pT category (P = 0.05) and advanced clinical stage (P = 0.03). In a proportional hazard model, BRAF(V600E) did not appear to be an independent risk factor for the faster recurrence (P = 0.784). We conclude that under the extensive thyroid surgery and limited application of radioiodine ablation BRAF(V600E) may not be an indicator of poorer disease-free survival during the short to middle follow-up period. However, it has a potential to contribute to patients stratification into high- and low-risk groups.
T2  - Endocrine Journal
T1  - Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia
VL  - 58
IS  - 5
SP  - 381
EP  - 393
DO  - 10.1507/endocrj.K11E-054
ER  - 
@article{
author = "Stanojević, Boban and Dzodic, Radan and Saenko, Vladimir and Milovanović, Zorka M. and Pupic, Gordana and Zivkovic, Ognjen and Markovic, Ivan and Đurišić, Igor and Buta, Marko and Dimitrijević, Bogomir B. and Rogounovitch, Tatiana and Mitsutake, Norisato and Mine, Mariko and Shibata, Yoshisada and Nakashima, Masahiro and Yamashita, Shunichi",
year = "2011",
abstract = "Molecular pathogenesis of papillary thyroid carcinoma (PTC) is largely associated with mutational changes in the BRAF, RAS family and RET genes. Our aim was to assess clinico-pathological and prognostic correlations of these PTC-specific gene alterations, with a particular emphasis on the BRAF mutation, in a group of 266 Serbian PTC patients, for the first time. The reference center-based retrospective cohort included 201 (75.6%) females and 65 (24.4%) males aged 48.0 +/- 16.1 years (8-83 years old, range) diagnosed and treated for PTC during 1993-2008. Follow-up period was 53.1 +/- 41.6 months (7-187 months, range). BRAF and RAS mutations were determined by direct sequencing of genomic DNA. RET/PTC rearrangements were analyzed by RT-PCR/Southern blotting. Genetic alterations were detected in 150/266 tumors (56.4%). One tumor displayed two genetic alterations. The BRAF(V600E) was found in 84/266 (31.6%) cases, RAS mutations in 11/266(4.1%) and RET/PTC in 55/266(20.7%; 42/266 (15.8%)RET/PTC1 and 13/266 (4.9%)RET/PTC3). On multivariate analysis BRAF(V600E) was associated with the classical papillary morphology (P = 0.05), the higher pT category (P = 0.05) and advanced clinical stage (P = 0.03). In a proportional hazard model, BRAF(V600E) did not appear to be an independent risk factor for the faster recurrence (P = 0.784). We conclude that under the extensive thyroid surgery and limited application of radioiodine ablation BRAF(V600E) may not be an indicator of poorer disease-free survival during the short to middle follow-up period. However, it has a potential to contribute to patients stratification into high- and low-risk groups.",
journal = "Endocrine Journal",
title = "Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia",
volume = "58",
number = "5",
pages = "381-393",
doi = "10.1507/endocrj.K11E-054"
}
Stanojević, B., Dzodic, R., Saenko, V., Milovanović, Z. M., Pupic, G., Zivkovic, O., Markovic, I., Đurišić, I., Buta, M., Dimitrijević, B. B., Rogounovitch, T., Mitsutake, N., Mine, M., Shibata, Y., Nakashima, M.,& Yamashita, S.. (2011). Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. in Endocrine Journal, 58(5), 381-393.
https://doi.org/10.1507/endocrj.K11E-054
Stanojević B, Dzodic R, Saenko V, Milovanović ZM, Pupic G, Zivkovic O, Markovic I, Đurišić I, Buta M, Dimitrijević BB, Rogounovitch T, Mitsutake N, Mine M, Shibata Y, Nakashima M, Yamashita S. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. in Endocrine Journal. 2011;58(5):381-393.
doi:10.1507/endocrj.K11E-054 .
Stanojević, Boban, Dzodic, Radan, Saenko, Vladimir, Milovanović, Zorka M., Pupic, Gordana, Zivkovic, Ognjen, Markovic, Ivan, Đurišić, Igor, Buta, Marko, Dimitrijević, Bogomir B., Rogounovitch, Tatiana, Mitsutake, Norisato, Mine, Mariko, Shibata, Yoshisada, Nakashima, Masahiro, Yamashita, Shunichi, "Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia" in Endocrine Journal, 58, no. 5 (2011):381-393,
https://doi.org/10.1507/endocrj.K11E-054 . .
30
28
31

Surgical treatment of papillary thyroid carcinoma in children and adolescents

Dzodic, Radan R.; Markovic, Ivan Z.; Đurišić, Igor; Buta, Marko; Pupic, Gordana; Milovanović, Zorka M.; Stanojević, Boban

(2010)

TY  - CONF
AU  - Dzodic, Radan R.
AU  - Markovic, Ivan Z.
AU  - Đurišić, Igor
AU  - Buta, Marko
AU  - Pupic, Gordana
AU  - Milovanović, Zorka M.
AU  - Stanojević, Boban
PY  - 2010
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/4037
C3  - Endocrine Journal
T1  - Surgical treatment of papillary thyroid carcinoma in children and adolescents
VL  - 57
SP  - S450
EP  - S450
ER  - 
@conference{
author = "Dzodic, Radan R. and Markovic, Ivan Z. and Đurišić, Igor and Buta, Marko and Pupic, Gordana and Milovanović, Zorka M. and Stanojević, Boban",
year = "2010",
journal = "Endocrine Journal",
title = "Surgical treatment of papillary thyroid carcinoma in children and adolescents",
volume = "57",
pages = "S450-S450"
}
Dzodic, R. R., Markovic, I. Z., Đurišić, I., Buta, M., Pupic, G., Milovanović, Z. M.,& Stanojević, B.. (2010). Surgical treatment of papillary thyroid carcinoma in children and adolescents. in Endocrine Journal, 57, S450-S450.
Dzodic RR, Markovic IZ, Đurišić I, Buta M, Pupic G, Milovanović ZM, Stanojević B. Surgical treatment of papillary thyroid carcinoma in children and adolescents. in Endocrine Journal. 2010;57:S450-S450..
Dzodic, Radan R., Markovic, Ivan Z., Đurišić, Igor, Buta, Marko, Pupic, Gordana, Milovanović, Zorka M., Stanojević, Boban, "Surgical treatment of papillary thyroid carcinoma in children and adolescents" in Endocrine Journal, 57 (2010):S450-S450.

Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source

Ivanović, Vesna; Dedović-Tanić, Nasta; Milovanović, Zorka M.; Lukić, Silvana; Nikolic, Srdjan; Baltic, Vladimir; Stojiljković, Bratislav; Budisin, Nikola; Savovski, Kiril; Demajo, Miroslav; Dimitrijević, Bogomir B.

(2009)

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Dedović-Tanić, Nasta
AU  - Milovanović, Zorka M.
AU  - Lukić, Silvana
AU  - Nikolic, Srdjan
AU  - Baltic, Vladimir
AU  - Stojiljković, Bratislav
AU  - Budisin, Nikola
AU  - Savovski, Kiril
AU  - Demajo, Miroslav
AU  - Dimitrijević, Bogomir B.
PY  - 2009
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2728
AB  - OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGF beta 1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC. STUDY DESIGN: The 6 selected malignant and autologous nonmalignant pairs of ALNT were fractionated, under special preanalytical, nonaggressive/nondenaturing conditions, to obtain respective cytoplasmic extracts for TGF beta 1 detection by the Quantikine (R and D Systems Inc., Minneapolis, Minnesota, U.S.A.) enzyme-linked immunosorbent assay kit. RESULTS: The data indicated a highly significant (r=0.973054) positive linear correlation between the TGF beta 1 concentration and total protein concentration in cytoplasmic extract of metastatic ALNT. The subsequent patients pilot study, performed strictly before any clinicopathologic factors were accessible, revealed significantly (p LT 0.01) elevated TGF beta 1 in malignant ALNT (median value: 1.05 ng/mg protein, range: 0.67-3.6 ng/mg protein, n=6) vs. autologous nonmalignant ALNT controls (median value: 0.48 ng/mg protein, range: 0.29-0.90 ng/mg protein, n=6). This elevation was correlated with the number of metastatic axillary lymph nodes with respect to the total and was consistent with an increase in size of tumor deposits in axillary lymph nodes. CONCLUSION: Our data provide for the first time suggestive evidence that the TGF beta 1 level in cytoplasmic extracts of metastatic ALNTs may be a promising bio-marker of invasiveness for BC patients. Confirmatory, large-scale studies are needed to evaluate possible implications of this putative biomarker in BC diagnosis and treatment. (Anal Quant Cytol Histol 2009;31:288-295)
T2  - Analytical and Quantitative Cytology and Histology
T1  - Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source
VL  - 31
IS  - 5
SP  - 288
EP  - 295
ER  - 
@article{
author = "Ivanović, Vesna and Dedović-Tanić, Nasta and Milovanović, Zorka M. and Lukić, Silvana and Nikolic, Srdjan and Baltic, Vladimir and Stojiljković, Bratislav and Budisin, Nikola and Savovski, Kiril and Demajo, Miroslav and Dimitrijević, Bogomir B.",
year = "2009",
abstract = "OBJECTIVE: To use cytoplasmic tissue extract as a new specimen source to quantify transforming growth factor beta 1 (TGF beta 1) protein in metastatic axillary lymph node tissue (ALNT) of breast cancer (BC) patients and to confirm the feasibility of this approach in a prospective pilot study on a subgroup of patients with invasive BC. STUDY DESIGN: The 6 selected malignant and autologous nonmalignant pairs of ALNT were fractionated, under special preanalytical, nonaggressive/nondenaturing conditions, to obtain respective cytoplasmic extracts for TGF beta 1 detection by the Quantikine (R and D Systems Inc., Minneapolis, Minnesota, U.S.A.) enzyme-linked immunosorbent assay kit. RESULTS: The data indicated a highly significant (r=0.973054) positive linear correlation between the TGF beta 1 concentration and total protein concentration in cytoplasmic extract of metastatic ALNT. The subsequent patients pilot study, performed strictly before any clinicopathologic factors were accessible, revealed significantly (p LT 0.01) elevated TGF beta 1 in malignant ALNT (median value: 1.05 ng/mg protein, range: 0.67-3.6 ng/mg protein, n=6) vs. autologous nonmalignant ALNT controls (median value: 0.48 ng/mg protein, range: 0.29-0.90 ng/mg protein, n=6). This elevation was correlated with the number of metastatic axillary lymph nodes with respect to the total and was consistent with an increase in size of tumor deposits in axillary lymph nodes. CONCLUSION: Our data provide for the first time suggestive evidence that the TGF beta 1 level in cytoplasmic extracts of metastatic ALNTs may be a promising bio-marker of invasiveness for BC patients. Confirmatory, large-scale studies are needed to evaluate possible implications of this putative biomarker in BC diagnosis and treatment. (Anal Quant Cytol Histol 2009;31:288-295)",
journal = "Analytical and Quantitative Cytology and Histology",
title = "Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source",
volume = "31",
number = "5",
pages = "288-295"
}
Ivanović, V., Dedović-Tanić, N., Milovanović, Z. M., Lukić, S., Nikolic, S., Baltic, V., Stojiljković, B., Budisin, N., Savovski, K., Demajo, M.,& Dimitrijević, B. B.. (2009). Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source. in Analytical and Quantitative Cytology and Histology, 31(5), 288-295.
Ivanović V, Dedović-Tanić N, Milovanović ZM, Lukić S, Nikolic S, Baltic V, Stojiljković B, Budisin N, Savovski K, Demajo M, Dimitrijević BB. Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source. in Analytical and Quantitative Cytology and Histology. 2009;31(5):288-295..
Ivanović, Vesna, Dedović-Tanić, Nasta, Milovanović, Zorka M., Lukić, Silvana, Nikolic, Srdjan, Baltic, Vladimir, Stojiljković, Bratislav, Budisin, Nikola, Savovski, Kiril, Demajo, Miroslav, Dimitrijević, Bogomir B., "Quantification of Transforming Growth Factor Beta 1 Levels in Metastatic Axillary Lymph Node Tissue Extracts from Breast Cancer Patients A New Specimen Source" in Analytical and Quantitative Cytology and Histology, 31, no. 5 (2009):288-295.
4

Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence

Veljkovic, E; Dzodic, R; Neskovic, G; Stanojević, Boban; Milovanović, Zorka M.; Opric, M; Dimitrijević, Bogomir B.

(2004)

TY  - JOUR
AU  - Veljkovic, E
AU  - Dzodic, R
AU  - Neskovic, G
AU  - Stanojević, Boban
AU  - Milovanović, Zorka M.
AU  - Opric, M
AU  - Dimitrijević, Bogomir B.
PY  - 2004
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/2836
AB  - Sequence alterations in the RET proto-oncogene are becoming increasingly important to clinical assessment of the malignant disease of the thyroid. A spectrum of mutations is necessary to establish comprehensive phenotype to genotype relationship relevant to diagnosis and therapy of thyroid malignancies. We aimed to append to the increasing database of these oncogenic lesions and, therefore, analyzed DNA from tumor tissue and constitutive DNA from a patient with thyroid carcinoma. Mutational screening and sequence characterization of the RET proto-oncogene was performed to include part of the intronic sequences. We report a germline sequence variant in DNA from the patient diagnosed with microfollicular thyroid carcinoma. The carcinoma presented not as fully developed medullar carcinoma (MTC) but as microfollicular carcinoma with tendency to evolve into MTC. We characterized the sequence variant located in the intron 10 of the RET oncogene as an A to G substitution denoted IVS10 + 4G. The described sequence alteration generates a chi-like sequence surrounded by several chi-like sequences with recombinational potential. Such alteration may be involved in the pathogenesis of the microfollicular carcinoma via genome destabilization through homologous recombination in the process of tumor progression. This result further substantiates the importance of the database correlating specific sequence variations in the RET gene with distinct disease phenotypes.
T2  - Medical Oncology
T1  - Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence
VL  - 21
IS  - 4
SP  - 319
EP  - 323
DO  - 10.1385/MO:21:4:319
ER  - 
@article{
author = "Veljkovic, E and Dzodic, R and Neskovic, G and Stanojević, Boban and Milovanović, Zorka M. and Opric, M and Dimitrijević, Bogomir B.",
year = "2004",
abstract = "Sequence alterations in the RET proto-oncogene are becoming increasingly important to clinical assessment of the malignant disease of the thyroid. A spectrum of mutations is necessary to establish comprehensive phenotype to genotype relationship relevant to diagnosis and therapy of thyroid malignancies. We aimed to append to the increasing database of these oncogenic lesions and, therefore, analyzed DNA from tumor tissue and constitutive DNA from a patient with thyroid carcinoma. Mutational screening and sequence characterization of the RET proto-oncogene was performed to include part of the intronic sequences. We report a germline sequence variant in DNA from the patient diagnosed with microfollicular thyroid carcinoma. The carcinoma presented not as fully developed medullar carcinoma (MTC) but as microfollicular carcinoma with tendency to evolve into MTC. We characterized the sequence variant located in the intron 10 of the RET oncogene as an A to G substitution denoted IVS10 + 4G. The described sequence alteration generates a chi-like sequence surrounded by several chi-like sequences with recombinational potential. Such alteration may be involved in the pathogenesis of the microfollicular carcinoma via genome destabilization through homologous recombination in the process of tumor progression. This result further substantiates the importance of the database correlating specific sequence variations in the RET gene with distinct disease phenotypes.",
journal = "Medical Oncology",
title = "Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence",
volume = "21",
number = "4",
pages = "319-323",
doi = "10.1385/MO:21:4:319"
}
Veljkovic, E., Dzodic, R., Neskovic, G., Stanojević, B., Milovanović, Z. M., Opric, M.,& Dimitrijević, B. B.. (2004). Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence. in Medical Oncology, 21(4), 319-323.
https://doi.org/10.1385/MO:21:4:319
Veljkovic E, Dzodic R, Neskovic G, Stanojević B, Milovanović ZM, Opric M, Dimitrijević BB. Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence. in Medical Oncology. 2004;21(4):319-323.
doi:10.1385/MO:21:4:319 .
Veljkovic, E, Dzodic, R, Neskovic, G, Stanojević, Boban, Milovanović, Zorka M., Opric, M, Dimitrijević, Bogomir B., "Sequence variant in the intron 10 of the RET oncogene in a patient with microfollicular thyroid carcinoma with medullar differentiation - Implications for newly generated chi-like sequence" in Medical Oncology, 21, no. 4 (2004):319-323,
https://doi.org/10.1385/MO:21:4:319 . .
2
2
2